GlassScriptPhysician profile
Mostafa M Rezk
NPI 1316238173
$2,083.35
in general payments reported to CMS, 2019-2025
27 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $202 · 2021: $298 · 2022: $277 · 2023: $369 · 2024: $602 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,202.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $415.26 | 2019-2025 | Wegovy |
| Glaxosmithkline, LLC. | $363.54 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $197.72 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $179.26 | 2022-2025 | Farxiga, Airsupra, Lokelma |
| Janssen Pharmaceuticals, INC | $140.90 | 2023-2024 | Spravato |
| Sanofi-Aventis U.S. LLC | $109.10 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.78 | 2019-2024 | Xifaxan, Trulance |
| Abbvie INC. | $84.09 | 2021-2025 | |
| Lilly USA, LLC | $83.88 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $39.96 | 2020-2022 | |
| Aytu Biopharma, INC. | $35.64 | 2021 | |
| Exact Sciences Corporation | $33.27 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $30.03 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.82 | 2022-2023 | |
| Esperion Therapeutics, INC. | $29.37 | 2021-2025 | Nexletol |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $28.14 | 2019-2020 | |
| Eisai INC. | $27.66 | 2020 | |
| Viatris Specialty LLC | $19.66 | 2025 | Yupelri |
| Xeris Pharmaceuticals, INC. | $18.73 | 2023 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company LTD. | $18.28 | 2022 | |
| Amarin Pharma, INC. | $16.35 | 2020 | |
| Paratek Pharmaceuticals, INC. | $15.26 | 2024 | Nuzyra |
| Arbor Pharmaceuticals, INC. | $15.05 | 2021 | |
| Avanir Pharmaceuticals, INC. | $14.95 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.76 | 2022 | |
| Intra-Sana Laboratories | $13.50 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Vifor Pharma, INC. | $13.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mostafa Rezk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.